COMMUNIQUÉS West-GlobeNewswire

Devenez membre PREMIUM

Accèdez sans limite aux 15 000 actualités du site
et recevez gratuitement chaque semaine,
la Newsletter Santé log avec les actus Santé à ne pas manquer !

S'abonner
29€ TTC/an

Je suis déjà membre PREMIUM

Se connecter

Immutep to Participate in Upcoming Investor Conferences
02/04/2025 - 14:00
SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces [...]
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
02/04/2025 - 14:00
Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026 Alignment through recent interactions with CDER on path to accelerated [...]
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
02/04/2025 - 14:05
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory [...]
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
02/04/2025 - 14:17
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili [...]
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
02/04/2025 - 14:30
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and [...]
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference
02/04/2025 - 14:30
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
02/04/2025 - 14:30
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that the FDA has approved an [...]
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
02/04/2025 - 14:30
HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that [...]
ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults
02/04/2025 - 10:00
Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adults Administration of INNA-051 to older adults (65 years old) in a Phase 1 study was well-tolerated and increased [...]
Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
02/04/2025 - 10:35
Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net sales Company prepares new product launches starting in 2025 Boehringer Ingelheim today announced [...]
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
02/04/2025 - 11:00
CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemia Final European Commission decision expected by June 2025; [...]
Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)
02/04/2025 - 11:00
Lugano, Switzerland – April 2, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive care, oncology and [...]
Curium Announces Approval of Generic DTPA - Kit for the Preparation of Technetium Tc 99m Pentetate Injection in the U.S.
02/04/2025 - 06:01
ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m Pentetate Injection, often [...]
IBA signe un contrat pour installer une solution Proteus®ONE au Tri-Service General Hospital à Taïwan
02/04/2025 - 07:00
Louvain-la-Neuve, Belgique, le 2 avril 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
IBA signs contract for a Proteus®ONE solution to be installed at the Tri-Service General Hospital in Taiwan
02/04/2025 - 07:00
Louvain-La-Neuve, Belgium, April 2 nd , 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the [...]
Zelluna ASA [ZLNA]: Annual Report 2024
02/04/2025 - 07:00
Oslo, Norway, 02 April, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces that the Board of Directors of [...]
Press Release Biocartis NV: Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay
02/04/2025 - 07:00
PRESS RELEASE 02/04/2025, 07:00 CEST Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay Mechelen, Belgium, 02 April 2025 – Biocartis NV (“Biocartis”), an innovative molecular diagnostics [...]
CMR Surgical secures more than $200M to accelerate growth
02/04/2025 - 08:00
CMR Surgical has closed a financing round of more than $200 million, backed by existing investors and new investor Trinity Capital The latest funding will fuel the global commercialisation of its Versius Surgical [...]
Respilean Drops Exposed (MUST-READ): The Truth About Lung Support Big Pharma Doesn’t Want You to Know
02/04/2025 - 02:29
Thousands Are Ditching Inhalers and Breathing Easier with This Surprising Lung Supplement Backed by Nature and Science JUPITER, FLORIDA, April 02, 2025 (GLOBE NEWSWIRE) -- RESPILEAN In a world where we measure [...]

Pages